title: Involvement of cholecystokinin within craving for cocaine: role of cholecystokinin receptor ligands.
abstract: In the brain, cholecystokinin (CCK) has been described to act as a central neurotransmitter or neuromodulator involved in functions such as food consumption, stress and anxiety. Recently, the CCK system has been involved in drug dependence phenomena and proposed to be correlated to a putative state of 'drug preferring' phenotype within free choice tests. CCK exerts its action in the CNS through at least two different G-protein coupled high affinity receptors, CCK1 and CCK2. Various selective CCK receptor agonists and antagonists have been synthesised. In particular, L-364,718 has been demonstrated to be a potent and selective CCK1 receptor antagonist, whereas L-365,260 is a potent and selective CCK2 receptor antagonist. More recently, GV150013 has been reported to be a highly selective CCK2 receptor antagonist. This paper reviews the putative role of the CCK system within drug dependence phenomena. In particular, it analyses the relationship between central CCK activity and the exhibition of spontaneous preference for drugs of abuse, such as cocaine or alcohol. The potential therapeutic role for CCK receptor antagonists is also discussed.
authors.affiliation: Department of Biology, Glaxo Wellcome SpA, Medicines Research Centre, via Fleming 4, 37100 Verona, Italy. fc20377@GlaxoWellcome.co.uk
authors.forename: F
authors.initials: F
authors.lastname: Crespi
authors.forename: M
authors.initials: M
authors.lastname: Corsi
authors.forename: A
authors.initials: A
authors.lastname: Reggiani
authors.forename: E
authors.initials: E
authors.lastname: Ratti
authors.forename: G
authors.initials: G
authors.lastname: Gaviraghi
mesh_terms: D000818:Animals; D016739:Behavior, Addictive / Q000188:drug therapy / Q000378:metabolism*; D002766:Cholecystokinin / Q000737:chemistry / Q000378:metabolism*; D019970:Cocaine-Related Disorders / Q000188:drug therapy / Q000378:metabolism*; D006801:Humans; D009714:Nucleus Accumbens / Q000378:metabolism*; D010641:Phenotype; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors* / Q000627:therapeutic use
chemical_list: D011949:Receptors, Cholecystokinin; D002766:Cholecystokinin